



## Publications and Presentations

### Cancer

Rixe O, Morris JC, Puduvalli VK, Villano JL, Wise-Draper TM, Muller C, Johnson AN, Wesolowski R, Qi X. **First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.** Poster Discussion Panel Session. American Society of Clinical Oncology (ASCO) Annual Meeting 2018.

Qi W, Davis HW, Chu Z, Vallabhapurapu, SD, Hussain N, Franco RS, Morris JC, Johnson AN, Olowokure, OO. **Combined effect of gemcitabine (GEM) and sapC-DOPS nanovesicles on pancreatic ductal adenocarcinoma (PDAC) in mice.** Accepted for publication 2018 ASCO Annual Meeting Proceedings

Cruze CA, Rixe O, Morris JC, Puduvalli VK, Villano JL, Wise-Draper TM, Johnson AN, Wesolowski R, Thompson GA. **Allometric scaling of preclinical pharmacokinetic and toxicokinetic parameters to predict clinical pharmacokinetics of BXQ-350 saposin C protein-phosphatidylserine nanovesicles.** Accepted for publication 2018 ASCO Annual Meeting Proceedings

Cruze CA, Rixe O, Morris JC, Puduvalli VK, Villano JL, Wise-Draper TM, Johnson AN, Wesolowski R. **Absence of indicators of hypercoagulability and antiphospholipid syndrome in bxq-350 first in human study.** Accepted for publication 2018 ASCO Annual Meeting Proceedings

Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia: A Retrospective Claims Analysis of Resource Utilization and Expenditures for Newly Diagnosed Patients From First-Line Induction to Remission and Relapse.** *Curr Med Res Opin.* 2017;33(3):519-527.

Irish W, Ryan MP, Gache LM, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia: A Retrospective Claims Analysis of Resource Utilization and Expenditures for De Novo Patients from First Line Induction to Remission and Relapse.** *Value Health.* 2016;19(3):A166.

Goldberg SL, Su Y, Gunnarsson C, Irish WD, Ryan M, Woloj M, Ferdinand R, Shapiro M. **The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.** *Blood.* 2015;126(23):2797.

Irish WD, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia (AML): A Retrospective Claims Analysis of Resource Utilization and Expenditures.** *Blood.* 2015;126(23):5633.

Mallow PJ, Chen J, Rizzo JA, Penrod JR, Trudel GC. **The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data.** *JHEOR.* 2015;3(1):83-96.

Goldberg SL, Su Y, Frame D, Ryan M, Irish WD, Gunnarsson C, Woloj M, Ferdinand R, Shapiro M. **Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.** *Haematologica.* 2015;100(s1):441.

Goldberg SL, Su Y, Frame D, Ryan M, Irish WD, Gunnarsson C, Woloj GM, Ferdinand R, Shapiro M. **Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.** *J Clin Oncol.* 2015;33(15\_suppl):e18026.

Mallow PJ, Chen J, Rizzo JA, Zyczynski TM, Penrod JR, Trudel GC. **The direct healthcare cost of prostate cancer: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Chen J, Mallow PJ, Rizzo JA, Zyczynski TM, Trudel GC, Penrod JR. **Cost of lost productivity due to prostate cancer: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Rizzo JA, Chen J, Penrod JR, Mallow PJ, Trudel GC, Zyczynski TM. **The labor productivity effects of prostate cancer patients on spouses and other family members: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Le TK, Zhang Y, Zyczynski TM. **Cost of metastatic castration-resistant prostate cancer in the United States.** *Value Health.* 2013;16(3):A136.

Zyczynski TM, Trudel GC, Chen J, Mallow PJ, Penrod JR, Rizzo JA. **The impact of prostate cancer on quality of life.** *Value Health.* 2013;16(3):A136.

## Cardiovascular Disease

Keuffel E, McCullough PA, Todoran TM, Brilakis ES, Palli SR, Ryan MP, Gunnarsson C. **The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty.** *J Med Econ.* 2018 Apr;21(4):356-364.

Gerdisch MW, Robinson S, David G, Makepeace S, Ryan MP, Gunnarsson C. **Clinical and Economic Benefits of Advanced Microplegia Delivery System in Cardiac Surgery: Evidence from 250 Hospitals** *Journal of Comparative Effectiveness Research* 2018 Epub ahead of print 2018 Apr

Malik R, Hunter TD, Parks C, Malik BR. **Touch-up and Recurrence Rates After Voltage Mapping for Verification of Pulmonary Vein Isolation (PVI) Following Cryoablation (CA) of Paroxysmal Atrial Fibrillation (PAF)** *Heart Rhythm*. 2018;15(5):S538.

Osorio J, Mallow PJ, Hunter TD, Imhoff RJ, Goldstein L, Rajendra A, Morales G. **Cost Minimization Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation (PAF) by Technology** *Heart Rhythm*. 2018;15(5):S425-426.

McCullough PA, David G, Todoran T, Brilakis ES, Ryan MP, Gunnarsson C. **Iso-Osmolar Contrast Media and Adverse Renal and Cardiac Events after Percutaneous Cardiovascular Intervention.** *J Comp Eff Res*. 2018 Apr;7(4):331-341

McCullough PA, David G, Todoran T, Brilakis ES, Ryan MP, Gunnarsson C. **Iso-Osmolar Contrast Media and Adverse Renal and Cardiac Events after Percutaneous Cardiovascular Intervention.** *Value Health*. 2017;20(9):A572.

Jarman JW, Hunter TD, Hussain W, March JL, Wong T, Markides V. **Stroke rates before and after atrial fibrillation ablation and in propensity-matched controls in the UK.** *Pragmat Obs Res*. 2017;8:107-118.

Jarman JW, Hunter TD, Hussain W, March JL, Wong T, Markides V. **Mortality, stroke and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts.** *Pragmat Obs Res*. 2017;8:99-106.

Gerdisch MW, Robinson SB, David G, Makepeace S, Ryan MP, Gunnarsson C. **Impact of the Adoption of Microplegia Delivery System: Clinical and Economic Analysis Using the Premier Database.** *Value Health*. 2017;20(5):A244.

Osorio J, Hunter TD, Bubien RS, Thorington S, Rajendra A, Arciniegas JG. **Efficiency and predictability in paroxysmal atrial fibrillation ablation with contact force catheter and stability module integration.** *Europace* 2017;19 (suppl\_3):iii371-iii372.

Osorio J, Hunter T, Bubien RS, Thorington S, Rajendra A, Arciniegas J. **A comparison of paroxysmal atrial fibrillation ablation efficiency and clinical outcomes across technologies in a high-volume center.** *Europace*. 2017;19 (suppl\_3):iii371.

De Potter T, Hunter TD, Boo LM, Chatzikyriakou S, Strisciuglio T, Silva Garcia E. **Ablation Efficiency with Contact Force Stability and Ablation Index in Paroxysmal Atrial Fibrillation.** *Heart Rhythm*. 2017;14(5S):S179.

Macle L, Frame D, Gache LM, Monir G, Pollak SJ, Boo LM. **Atrial Fibrillation Ablation using a Thermocool SmartTouch Catheter Compared to Non-Contact-Force Catheters: A Systematic Review and Meta-Analysis.** *Heart Rhythm*. 2017;14(5S):S461–S462.

Moore M, Barnhart GR, Chitwood WR Jr., Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The economic value of rapid deployment aortic valve replacement via full sternotomy.** *J Comp Eff Res.* 2017;6(4):293-302.

Biviano AB, Hunter TD, Dandamudi G, Fishel RS, Gidney B, Herweg B, Oza SR, Patel AM, Wang H, Pollak SJ. **Healthcare Utilization and Quality of Life Improvement after Ablation for Paroxysmal AF in Younger and Older Patients.** *Pacing Clin Electrophysiol.* 2017;40(4):391-400.

Lip GY, Hunter TD, Quiroz ME, Ziegler PD, Turakhia MP. **Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke.** *Circ Cardiovasc Qual Outcomes.* 2017;10(1):e002864.

Moore M, Chen J, Mallow PJ, Rizzo JA. **The direct health-care burden of valvular heart disease: evidence from US national survey data.** *Clinicoecon Outcomes Res.* 2016;8:613-627.

Moore, M, Barnhart GR, Chitwood WR Jr., Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The Economic Value of Rapid Deployment Aortic Valve Replacement via Full Sternotomy.** *Value Health.*2016;19(7):A645.

Lebehn M, Hunter T, Clancy S, Spies C. **Effects of anesthesia on cost and length of stay in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) – Results from a Cohort Study.** *J Am Coll Cardiol.* 2016;68(18\_S):B278.

Lebehn M, Hunter T, Clancy S, Spies C. **A comparison of the effects on length of stay and cost with percutaneous versus surgical cutdown femoral artery access in patients undergoing Transcatheter Aortic Valve Replacement – Results from a Cohort Study.** *J Am Coll Cardiol.* 2016;68(18\_S):B152.

Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ. **Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence from a Large US Payer Database 1-Year Post Implantation.** *Circ Arrhythm Electrophysiol.* 2016; 9(8):e003929.

Moore M, Barnhart GR, Chitwood WR Jr, Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The economic value of INTUITY in aortic valve replacement.** *J Med Econ.* 2016;19(10):1011-1017.

Hunter TD, Palli SR, Rizzo, JA. **Cost comparison of radiofrequency catheter ablation versus cryoablation for atrial fibrillation in hospitals using both technologies.** *J Med Econ.* 2016;19(10):959-964.

Clancy S, Womeldorff J, Ryan MP. **Operating Room Variable Cost of Transcatheter Aortic Valve Replacement.** *Value Health.* 2016;19(3):A47.

Ladapo JA, Turakhia MP, Ryan MP, Mollenkopf SA, Reynolds ME. **Healthcare Utilization and Expenditures Associated With Remote Monitoring in Patients With Implantable Cardiac Devices.** *Am J Cardiol.* 2016;117(9):1455-1462.

Hunter TD, Palli S, Mallow PJ, Rizzo, JA. **Cost Comparison of Radiofrequency Catheter Ablation versus Cryoablation for Atrial Fibrillation in Hospitals Using Both Technologies.** *Heart Rhythm.* 2016;13(Supplement 5):S120.

Mallow PJ, Johnson M, Lim L, David G. **Contrast Media Selection in Inpatient Interventional Cardiovascular Procedures.** Oral presentation at *China Interventional Therapeutics (CIT 2016)*, March 17-20, 2016, Beijing, China.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Interventional & Diagnostic Cardiovascular Procedures.** Poster presented at *China Interventional Therapeutics (CIT 2016)*, March 17-20, 2016, Beijing, China.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Cardiovascular Procedures.** Poster presented at the *Cardio-Renal Metabolic Conference (CRSA)*, March 12, 2016, Scottsdale, AZ, USA.

Mallow PJ, Chen J, Moore M, Rizzo JA. **The Direct Healthcare Expenditures of Mitral Valve Disease: Evidence From US National Survey Data.** *Circ Cardiovasc Qual Outcomes.* 2016;9(Suppl\_2):A258.

Chen J, Mallow PJ, Moore M, Rizzo JA. **The Direct Healthcare Expenditures of Aortic Valve Disease: Evidence From US National Survey Data.** *Circ Cardiovasc Qual Outcomes.* 2016;9(Suppl\_2):A257.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Cardiovascular Procedures.** Poster presented at *AKI & CRRT 2016 21<sup>st</sup> International Conference on Advances in Critical Care Nephrology*, February 16-19, 2016, San Diego, CA, USA.

David G, Johnson M, Lim L, Mallow PJ. **The Effect of the Choice of Contrast Media on Contrast-Induced Acute Kidney Injury Events in Inpatient Interventional or Diagnostic Cardiovascular Procedures.** *J Am Coll Cardiol.* 2015;66(15\_S):B151-B152.

Nazarian S, Reynolds MR, Ryan MP, Wolff SD, Mollenkopf SA, Turakhia MP. **Utilization and likelihood of radiologic diagnostic imaging in patients with implantable cardiac defibrillators.** *J Magn Reson Imaging.* 2015;43(1):115-127.

Chyou JY, Hunter TD, Mollenkopf SA, Turakhia MP, Reynolds MR. **Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients.** *J Am Heart Assoc.* 2015;23;4(7):e001723.

Khaykin Y, Mallow PJ, Rizzo JA, Verma A, Chun L, Olesovsky S, Reynolds MR. **Cost-effectiveness of Catheter Ablation versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.** *JHEOR*. 2015;3(1):1-12.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The effect of the choice of contrast media on MARCE events in angioplasty procedures.** *EuroIntervention*. 2015. Abstracts EuroPCR May 2015:POS062.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The effect of the choice of contrast media on kidney events in angioplasty procedures.** *EuroIntervention*. 2015. Abstracts EuroPCR May 2015:POS064.

Nazarian S, Reynolds MR, Ryan MP, Wolff SD, Mollenkopf S, Turakhia MP. **Evidence of a gap in care: utilization of Radiologic Diagnostic imaging in patients with and without implantable defibrillators.** *Value Health*. 2015;18(3):A47.

Gunnarsson C, Lim S, David G, Riebman JB, Martin L, Kocharian R. **The Incremental Cost of Reoperations for Bleeding Events in Cardiac and Vascular Reconstructive Surgery.** *Value Health*. 2015;18(3):A140.

Rizzo JA, Chen J, Mallow PJ, Moore M. **The Total Direct Healthcare Cost of Aortic and Mitral Valvular Disease: Evidence from US National Survey Data.** *Value Health*. 2015;18(3):A144.

Jarman JWE, March JL, Hunter TD. **Stroke Rates after Pulmonary Vein Isolation Ablation versus a Matched Control Cohort.** *Heart Rhythm*. 2015;12(Supplement 5):S428.

Jarman JWE, March JL, Boo LM, Hunter TD **Comparison of Stroke and Heart Failure Survival in a Large UK Population with Atrial Fibrillation Treated with Pulmonary Vein Isolation Ablation versus a Matched Control Cohort.** *Heart Rhythm*. 2015;12(Supplement 5):S429.

Nazarian S, Reynolds MR, Ryan MP, Hunter TD, Wolff SD, Mollenkopf SA, Turakhia MP. **Estimating the Likelihood of MRI in Patients after ICD Implantation: A 10-Year Prediction Model.** *J Am Coll Cardiol*. 2015;65(10S):A1090.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Angioplasty Procedures.** *Catheter Cardiovasc Interv*. 2015;85(Supplement S2):S37

Grossi EA, Moore M, Mallow PJ, Rizzo JA. **The Cost of an Operating Room Minute for Heart Valve Procedures.** *JHEOR*. 2015;2(2):170-80.

Hunter TD, Lip GY, Quiroz ME, Mollenkopf SA, Turakhia MP. **Cryptogenic Strokes and Second Ischemic Stroke Rates in Relation to the CHADS2 and CHA2DS2-VASc Risk Scores.** *Stroke*. 2015;46(Suppl 1):AWP189.



Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR. **International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.** *Curr Med Res Opin.* 2014;30(12):2437-2442.

Mallow PJ, Baniewicz J, Williams JM, Au-Yeung A. **A Cost Comparison Analysis of Medtronic's Stent Graft System to Competition for Endovascular Aneurysm Repair for Abdominal Aortic Aneurysms.** *Value Health.* 2014;17(7):A482.

Ladapo J, Turakhia MP, Landry-Wilson EM, Ryan MP, Irish W, Mollenkopf SA, Reynolds MR. **Remote Monitoring of Implantable Cardiovascular Devices is Associated with Reductions in Healthcare Utilization.** *Heart Rhythm* 2014;11(5):S1-S626.

Khaykin Y, Mallow PJ, Rizzo JA, Verma A, Chun L, Olesovsky S, Reynolds MR. **Cost-effectiveness of Catheter Ablation vs. Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.** *Heart Rhythm* 2014;11(5):S1-S626.

Reynolds MR, David G, Gunnarsson C, March JL, Hao SC. **The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation.** *JHEOR* 2014;2(1):15-28.

Oza SR, Hunter TD, Biviano AB, Dandamudi G, Herweg B, Patel AM, Pollak SJ, Wang H, Fishel RS. **Acute safety of an open-irrigated ablation catheter with 56-hole porous tip for radiofrequency ablation of paroxysmal atrial fibrillation: analysis from 2 observational registry studies.** *J Cardiovasc Electrophysiol* 2014;25(8):852-858.

Hunter TD, Quiroz ME, Gunnarsson C, Mollenkopf SA. **Characterization of Ischemic Stroke Patients and Second Stroke Rates by Risk Scores.** *Value Health.* 2014;17(3):A104.

Mallow PJ, Rowlandson I, Tasic D. **Outpatient Visits to the Cath Lab for Coronary Angiography Resulting in Minimal Action in the Short Term.** *Value Health.* 2014;17(3):A153.

Moore M, Mallow PJ, Rizzo JA. **The Variable Cost of an Operating Room Minute for Valvular Procedures.** *Value Health.* 2014;17(3):A112.

Mallow PJ, Rizzo JA. **Benefits of Managing Low-Density Lipoprotein Particles (LDL-P) in Conjunction with Low-Density Lipoprotein Cholesterol (LDL-C) for the Avoidance of Cardiovascular Disease Events: A Cost-Effectiveness Analysis.** Poster presented at *25th Annual National Forum on Quality Improvement in Health Care* December 8-11, 2013, Orlando, FL, USA.

Rodriguez R, Malaisrie SC, Mehall JR, Salemi A, Ailawadi G, Ryan W, Moore M, Gunnarsson C, Grossi EA. **Impact of surgical approach for aortic replacement on**

**outcomes and cost: a multi-institution analysis of "real world" data.** Podium presentation at *The Society of Thoracic Surgeons (STS) 50th Annual Meeting* January 25-29, 2014, Orlando, FL, USA.

Phiri D, Mallow P, Rizzo JA. **The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking.** *JHEOR* 2013;1(2):96-107.

Rizzo JA, Mallow PJ, Waters HC, Pokrywka GS. **Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effective analysis.** *J Clin Lipidol.* 2013;7(6):642-652.

Mallow PJ, Hsiao CW, Rizzo JA. **Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation in Canada.** *Value Health.* 2013;16(3):A289.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **Identification of patients at high risk for subsequent development of atrial fibrillation or stroke using a claims database.** *Value Health.* 2013;16(3):A25.

Turakhia MP, Reynolds MR, Gunnarsson CL, Swain AL, Mollenkopf SA, Zweibel SL. **Healthcare resource utilization and expenditures associated with implantable cardioverter defibrillator shocks.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A3.

Gunnarsson C, Rizzo JA, Burton ML, Mollenkopf SA, Brill SL, Tsintzos S. **Cost Profile of Heart Failure Inpatient Admissions in the United States: Data from the Premier Hospital Database.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A66.

Turakhia MP, Hunter TD, Mollenkopf SA, Reynolds MR. **Rates of Atrial Fibrillation Diagnoses and Stroke Events by Combination of Risk Factors.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A239.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **What risk factors cause both incident AF and stroke? An analysis of 1.8 M at-risk U.S. patients.** *Heart Rhythm.* 2013;10(5):S292.

Gunnarsson CL, Ryan MP, Turakhia MP, Wolff SD, Swain AL, Mollenkopf SA, Reynolds MR. **Radiology utilization in patients with and without pacemakers, evidence of a gap in care.** *Heart Rhythm.* 2013;10(5):S292-S293.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **Extremely low use of ambulatory cardiac monitoring among American insured patients with arrhythmia-related symptoms at high risk of AF or stroke.** *J Am Coll Cardiol.* 2013;61(10\_S):E301.



Reynolds MR, David G, Gunnarsson C, March J, Zhang M, Hao SC. **The effects of catheter ablation treatment on medication use and expenditures in patients with atrial fibrillation.** *Circulation*. 2012;126(21 Supplement):A16555.

Rizzo JA, Mallow P, Cirrincione A. **Forecasting the prevalence and economic burden of atrial fibrillation in selected countries, 2010-2025.** *Value Health*. 2012;15(7):A351.

Rizzo JA, Mallow P, Cirrincione A. **The economic burden of atrial fibrillation among elderly populations in selected developed countries.** *Value Health*. 2012;15(7):A352.

Rizzo JA, Mallow P, Cirrincione A. **Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation in the UK.** *Value Health*. 2012;15(7):A357.

Phiri D, Mallow P, Rizzo JA. **The cost effectiveness of hand held ultrasound scanning for AAA in elderly subjects with a history of smoking.** *Value Health*. 2012;15(7):A356.

Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GY. **Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey.** *Br J Gen Pract*. 2012;62(603):e710-717.

Hao SC, Hunter TD, Gunnarsson C, March JL, White SA, Ladapo JA, Reynolds MR. **Acute safety outcomes in younger and older patients with atrial fibrillation treated with catheter ablation.** *J Interv Card Electrophysiol*. 2012;35(2):173-182.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **Estimating the economic burden of atrial fibrillation in selected developing countries.** *Value Health*. 2012;15(4):A64.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **The economic burden of atrial fibrillation among elderly populations in selected developed countries.** *Value Health*. 2012;15(4):A64.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **Forecasting the prevalence and economic burden of atrial fibrillation in selected countries, 2010 – 2025.** *Value Health*. 2012;15(4):A64-A65.

Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, Hao SC. **Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity matched analysis.** *Circ Cardiovasc Qual Outcomes*. 2012;5(2):171-181.

Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN. **Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans.** *J Am Coll Cardiol*. 2011;58(5):530-537.

Ladapo JA, David G, Gunnarsson CL, Hao SC, White SA, March JL, Reynolds MR. **Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.** *J Cardiovasc Electrophysiol.* 2012;23(1):1-8.

Hunter TD, Gunnarsson C, Bullano MF, de Vane PJ. **Is cardiovascular medication usage a marker for cardiovascular risk? Potential implication for smart-edit formulary management strategies.** *Value Health.* 2011;14(3):A50.

Ladapo JA, David G, Gunnarsson CL, Hao S, White S, March J, Zhang M, Reynolds M. **Reduction in healthcare utilization and expenditures in patients treated with catheter ablation for atrial fibrillation (AF) in the United States.** *Value Health.* 2011;14(3):A88.

Reynolds MR, Gunnarsson C, Hunter T, Ladapo J, March J, White SA, Zhang M, Hao SC. **Comparison of long term stroke or TIA risk between patients with atrial fibrillation who undergo radiofrequency catheter ablation vs. matched patients who have not had an ablation procedure.** *J Am Coll Cardiol.* 2011;57(14s1):E59.

Pilz G, Patel PA, Fell U, Ladapo JA, Rizzo JA, Fang H, Gunnarsson C, Heer T, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary artery disease: a net cost analysis and reimbursement implications.** *Int J Cardiovasc Imaging.* 2011;27(1):113-121.

Cload P, Kallenbach L, Ross S, Haas S, Gunnarsson C. **Impact of a seminal study on practice patterns: statin use before and after the JUPITER study.** *Value Health.* 2010;13(3):A177.

Pilz G, Patel P, Fell U, Rizzo J, Fang H, Gunnarsson C, Graw M, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary artery disease: a net cost analysis and reimbursement implications.** *J Cardio Magn Reson.* 2010;12(Suppl1):P295.

Budoff MJ, Karwasky R, Ahmadi N, Nasserian C, Pratt F, Stephens J, Chang WW, Flores FR, Rizzo JA, Gunnarsson CL, McKay CR. **Cost-effectiveness of multidetector computed tomography compared with myocardial perfusion imaging as gatekeeper to invasive coronary angiography in asymptomatic firefighters with positive treadmill tests.** *J Cardiovasc Comput Tomogr.* 2009;3(5):323-330.

Cload P, Marelli, C, Ross S, Zyczynski T, Haas S, Gunnarsson C. **Using electronic medical records (EMRS) to assess anticoagulation status according to stroke risk in patients with atrial fibrillation in ambulatory care settings.** *Value Health.* 2009;12(7):A320.

Pilz G, Patel P, Fell U, Rizzo R, Fang H, Gunnarsson C, Graw M, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary**

**artery disease: a net cost analysis & reimbursement implications.** *Value Health.* 2009;12(7):A344.

## Circulatory System

Ryan MP, Mustapha J, Gunnarsson C, Martinsen BJ, Adams G. **The Hospital Burden of Amputation in Patients with Peripheral Artery Disease.** Poster accepted for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting May 19-23, 2018 in Baltimore, MD, USA

Shammas NW, Boyes CW, Palli SR, Rizzo JA, Martinsen BJ, Kotlarz H, Mustapha JA. **Hospital cost impact of orbital atherectomy with angioplasty for critical limb ischemia treatment: a modeling approach.** *J Comp Eff Res.* 2018 Apr;7(4):305-317.

Armstrong EJ, Ryan MP, Baker ER, Martinsen BJ, Kotlarz H, Gunnarsson C. **Risk of Major Amputation or Death among Patients with Critical Limb Ischemia Initially Treated with Endovascular Intervention, Surgical Bypass, Minor Amputation, or Conservative Management.** *J Med Econ.* 2017;20(11):1148-1154.

Rizzo JA, Chen J, Laurich C, Santos A, Martinsen, BJ, Ryan MP, Kotlarz H, Gunnarsson C. **Racial Disparities in PAD Related Amputation Rates among Native Americans and non-Hispanic Whites: an HCUP Analysis.** *J Health Care Poor Underserved.* 2018;29(2):782-800.

Gunnarsson C, **Economics of and Disparities in Care for Critical Limb Ischemia.** Oral presentation at *The Amputation Prevention Symposium (AMP)*, August 9-12, 2017, Chicago, IL, USA.

Gunnarsson C, **Racial Disparities among Native Americans with Peripheral Artery Disease.** Oral presentation at *Outpatient Endovascular and interventional Society (OEIS)*, March 31-April 2, 2017, Santa Monica, CA, USA.

Gunnarsson, C, Chambers JW, Ryan MP, Baker ER, Kotlarz H, Martinsen BJ. **Atherectomy Utilization Shows Lower Odds of Adverse Events during Outpatient Percutaneous Coronary Interventions Compared to Angioplasty Alone.** *Value Health.* 2017;20(5):A267.

Gunnarsson, C, Lee MS, Ryan MP, Kotlarz H, Martinsen BJ. **Prevalence of Patients with Peripheral and Coronary Artery Disease.** *Value Health.* 2017;20(5):A267.

Palli SR, Rizzo JA, Martinsen BJ, Kotlarz H. **An Incremental Cost Analysis of Orbital Atherectomy Plus Angioplasty Compared to Angioplasty Alone for the Treatment of Critical Limb Ischemia.** *Value Health.* 2017;20(5):A266.

Gunnarsson C, Ryan MP, Boyes CW, Bolden PL, Baker ER, Kotlarz H, Martinsen BJ, Mustapha JA. **Risk of Major Amputation or Death among Peripheral Artery Disease Patients with Critical Limb Ischemia across Treatment Pathways.** *Value Health.* 2017;20(5):A266.

Gunnarsson C, Adams GL, Ryan MP, Kotlarz H, Martinsen BJ. **The Hospital Burden of Major Amputation Due to Peripheral Artery Disease in the United States.** *Value Health.* 2017;20(5):A266.

Mustapha JA, Fisher, Sr. BT, Rizzo JA, Chen J, Martinsen BJ, Kotlarz H, Ryan MP, Gunnarsson C. **Explaining Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease (PAD) using Decomposition Methods.** *J Racial Ethn Health Disparities.* 2016. Accepted for publication.

Zhao R, Gunnarsson C, Kotlarz H, Martinsen BJ, Palli S, Bell E, Rizzo JA. **An Incremental Cost Analysis of Orbital Atherectomy Plus Angioplasty Compared to Angioplasty Alone for the Treatment of Critical Limb Ischemia.** *Value Health.* 2016;19(3):A45.

Palli S, Gunnarsson C, Kotlarz H, Martinsen BJ, Zhao R, Rizzo JA. **Impact of a Limb Salvage Program on the Economic Burden of Amputation in the United States.** *Value Health.* 2016;19(3):A45.

Mustapha JA, Fisher, Sr. BT, Rizzo JA, Chen J, Martinsen BJ, Kotlarz H, Ryan MP, Gunnarsson C. **Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease using the Healthcare Cost and Utilization Project Database.** *Value Health.* 2016;19(3):A55-A56.

Rizzo JA, Chen J, Laurich C, Santos A, Martinsen BJ, Ryan MP, Kotlarz H, Gunnarsson C. **Racial Disparities in Amputation Rates among Native Americans with Peripheral Artery Disease: Analysis of the Healthcare Cost and Utilization Project Database.** *Value Health.* 2016;19(3):A55.

Rizzo JA, Chen J, Kotlarz H, Martinsen BJ, Ryan MP, Palli S, Gunnarsson C. **Racial Disparities in Amputation Rates for Patients with Peripheral Artery Disease: Long-Term Trends and Projections to 2020.** *Value Health.* 2016;19(3):A55.

## **Dermatology**

Carter C, Schenkel B, Waters H, Haas S. **Real-world treatment patterns for the first year of ustekinumab therapy in patients with moderate to severe psoriasis.** *J Am Acad Dermatol.* 2013;68(4):AB209-Supplement 1.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey.** *J Dermatolog Treat.* 2012;23(4):240-254.

Lofland J, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct medical costs of psoriasis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A206-A207.

## Dysphagia

Plessinger D, Ryan MP, Gache LM, Baker ER, Gunnarsson C. **Dysphagia: A Retrospective Payer Database Analysis to Understand Patient Characteristics and Comorbid Profiles.** *Dysphagia (Abstracts)* 2017 32:799–858

Plessinger D, Ryan MP, Gache LM, Gunnarsson C, Faught RE. **Estimating the Incremental Burden of Dysphagia in Epilepsy Patients: A Retrospective Payer Database Analysis.** AES 2016 Annual Meeting Abstract Database. AESnet.org.

## Economic Model

Van den Wyngaert T, Palli SR, Imhoff RJ, Hirschmann MT. **Cost-Effectiveness of Bone SPECT/CT in Painful Total Knee Arthroplasty.** *Journal of Nuclear Medicine* 2018, Mar Epub ahead of print.

Toney LK, Kim RD, Palli, SR. **The Economic Value of Hybrid Single-Photon Emission Computed Tomography with Computed Tomography Imaging in Pulmonary Embolism Diagnosis.** *Acad Emerg Med.* 2017 Sep;24(9):1110-1123.

Ammerman RT, Mallow PJ, Rizzo JA, Putnam FW, Van Ginkel JB. **Cost-effectiveness of In-Home Cognitive Behavioral Therapy for low-income depressed mothers participating in early childhood prevention programs.** *J Affect Disord.* 2017;208:475-482.

Rizzo JA, Rudmik L, Mallow PJ, Palli SR. **Budget impact analysis of bioabsorbable drug-eluting sinus implants following endoscopic sinus surgery.** *J Med Econ.* 2016;19(9):829-835.

Rudmik L, Mallow PJ, Palli S, Rizzo JA. **Budget Impact Analysis of Bioabsorbable Drug-Eluting Sinus Implants for Endoscopic Sinus Surgery.** *Value Health.* 2015;18(7):A368.

Ammerman RT, Chen J, Mallow PJ, Rizzo JA, Folger AT, Van Ginkel JB. **Annual direct health care expenditures and employee absenteeism costs in high-risk, low-income mothers with major depression.** *J Affect Disord.* 2015;190:386-394.

Ammerman RT, Chen J, Mallow PJ, Rizzo JA, Folger AT, Van Ginkel JB. **Annual Direct Health Care Expenditures and Employee Absenteeism Costs in High-Risk, Low-Income Mothers with Major Depression.** Oral presentation at the *Perinatal Mental Health Conference*, November 4-6, 2015, Chicago, IL, USA.

Mallow PJ, Irish W, Rizzo JA. **Pricing, Economics, Reimbursement, Market Share (PERMS) Strategy: An Interactive Holistic Approach for Rare Diseases.** Podium presentation at *Drug Information Association (DIA) 50<sup>th</sup> Annual Meeting*, June 15-19, 2014, San Diego, CA, USA.

Mallow PJ, Rizzo JA, Irish W, Okere CE. **A Comprehensive Economic and Pricing Modeling Framework for Understanding Orphan Drug Development.** *Value Health.* 2014;17(3):A205.

## Endocrine Disorders/Obesity

Palli SR, Rizzo JA, Heidrich N. **Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective.** *Obes Surg.* 2018 Epub ahead of print

Heidrich N, Palli SR. **The Short- and Long-Term Economic Impact of Bariatric Surgery Coverage for a Payer.** Poster accepted for presentation at *ObesityWeek 2017* October 29-November 2, 2017, Washington, DC, USA.

Gunnarsson C, Ryan MP, Marelli C, Baker ER, Stewart PM, Johannsson G, Biller BMK. **Health Care Burden in Patients With Adrenal Insufficiency.** *J Endocr Soc.* 2017;1(5):512:523.

Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G. **Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.** *J Clin Endocrinol Metab.* 2016;101(12):4843-4850.

Stewart PM, Biller BMK, Marelli C, Gunnarsson C, Ryan M, Johannsson G. **Increased morbidity and hospital admissions in patients with adrenal insufficiency.** *Endocrine Abstracts.* 2016;41:GP16.

Ghosh SK, Ryan MP, Gache LM, Roy S, Fegelman E. **Differences in Clinical Outcomes and Costs Associated with the Use of Staple Line Buttress In Bariatric Surgery.** *Value Health.* 2016;19(3):A246.

Hatoum IJ, Blackstone R, Hunter TD, Francis DM, Steinbuch M, Harris JL, Kaplan LM. **Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery.** *JAMA Surg.* 2016;151(2):130-137.

Boscoe A, Ryan M, Iloeje U, Kincaid J, Irish W, Laurence J. **Early Access to Eculizumab Improves Clinical Outcomes and Reduces In-Hospital Resource Use in Patients with Atypical Hemolytic Uremic Syndrome (aHUS).** Poster presented at *American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition*, December 6-10, 2015, New Orleans, LA, USA.



Irish W, Boscoe A, Ryan MP, Iloeje U, Gunnarsson C, Marks W. **Economic Burden of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis using the Premier Hospital Database.** *Value Health.* 2015;18(3):A187.

Stewart P, Biller BMK, Marelli C, Gunnarsson C, Ryan M, Johannsson G. **Defining and exploring the excessive healthcare burden of Adrenal Insufficiency.** *Endocrine Abstracts.* 2015;37:GP.01.02.

David G, Gill M, Gunnarsson C, Shafiroff J, Edelman S. **Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes.** *Am J Manag Care.* 2014;20(11):e490-e497.

Benoit SC, Hunter TD, Francis DM, De La Cruz-Munoz N. **Use of Bariatric Outcomes Longitudinal Database (BOLD) to Study Variability in Patient Success after Bariatric Surgery.** *Obes Surg* 2014;24(6):936-43.

Holt TA, Gunnarsson CL, Cload PA, Ross SD. **Identification of undiagnosed diabetes and quality of diabetes care in the United States: cross-sectional study of 11.5 million primary care electronic records.** *CMAJ Open* 2014;2(4):E248-255.

Holt TA, Gunnarsson C, Cload P, Ross S. **Identification of undiagnosed diabetes and quality of diabetes care in the US: Retrospective observational cohort analysis using electronic records.** *Prim Health Care Res Dev.* 2013;14(S1):1-106.

Benoit SC, Francis DM, Hunter TD. **Analysis of bariatric outcomes longitudinal database (BOLD) to predict percent BMI loss after bariatric surgery.** *Value Health.* 2012;15(4):A73-A74.

Hatoum IJ, Hunter TD, Francis DM, Steinbuch M, Kaplan LM. **Identification of bariatric surgical procedures, comorbidities and adverse events in payor data.** *Value Health.* 2012;15(4):A80.

David G, Shafiroff J, Saulnier A, Gunnarsson C. **Multiple daily injection therapy (MDI) versus durable insulin pump therapy in Type II diabetics: a breakeven analysis.** *Value Health.* 2012;15(4):A65.

Benoit S, Hunter TD, Steinbuch M, Fegelman E, Francis D, Seeley R. **Using electronic medical records to identify potential predictors for bariatric surgery success.** *Value Health.* 2011;14(3):A86.

Crawford AG, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, Haas S, Nigam SC, Schuette R. **Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database.** *Popul Health Manag.* 2010;13(3):151-161.

Cload P, Zyczynski T, Ross S, Haas S, Gunnarsson C. **Underuse of BMD measurements and bisphosphonate treatment in women over age 50 with**

**osteoporosis in a nationally-representative EMR database.** *Value Health.* 2010;13(3):A131.

Marelli C, Cload P, Zyczynski T, Ross S, Gunnarsson C, Haas S. **Using electronic medical records to identify undiagnosed diabetes mellitus in primary care practices.** *Value Health.* 2009;12(7):A234.

Cawley J, Rizzo J, Gunnarsson C, Haas K. **The health care costs effects of diabetes among obese and morbidly obese adults in the United States.** *Value Health.* 2008;11(3):A156.

Cawley J, Rizzo J, Haas K (For S<sup>2</sup> Statistical Solutions, Inc.). **The association of diabetes with job absenteeism costs among obese and morbidly obese workers.** *J Occup Environ Med.* 2008;50(5):527-534.

Cawley J, Rizzo J, Haas K (For S<sup>2</sup> Statistical Solutions, Inc). **Occupation-specific absenteeism costs associated with obesity and morbid obesity.** *J Occup Environ Med.* 2007;48(12):1317-1324.

## **Gastrointestinal Disease**

David G, Gunnarsson C, Lofland JH. **Variations in Care: A Retrospective Database Analysis of Healthcare Utilization Patterns for Patients with Inflammatory Bowel Disease.** *J Med Econ.* 2015;18(2):137-144.

Ghosh SK, Roy S, Ryan MP, Gunnarsson C, Yoo AC. **Incremental Burden of Anastomotic Leaks in Colorectal Surgeries.** *Value Health.* 2014;17(3):A78.

David G, Mallow PJ, Cantu H, Lofland J. **Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients with Inflammatory Bowel Disease.** *Gastroenterology.* 2014;146(5):S-434.

Mallow P, Rizzo J, Gathany T, Lofland J. **Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Adalimumab, Golimumab, and Infliximab Among Patients with Ulcerative Colitis (UC).** Poster presented at *Crohn's & Colitis Foundation's Clinical & Research Conference* December 12-14, 2013, Hollywood, FL, USA.

Mallow P, Rizzo J, Gathany T, Lofland J. **Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis: Results from PURSUIT-Maintenance.** Poster presented at *Crohn's & Colitis Foundation's Clinical & Research Conference* December 12-14, 2013, Hollywood, FL, USA.

David G, Gunnarsson CL, Lofland J, Goodney P, Siegel CA. **Geographic Variation in Care of Patients with Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States.** *Gastroenterology.* 2013 144(5)Supplement 1:S647.

Mallow PJ, Rizzo JA, Queener MK, Gathany TA, Lofland J. **Cost per clinical remission and clinical response of adalimumab, golimumab and infliximab in the treatment of patients with ulcerative colitis: an induction analysis.** *Am J Gastroenterol.* 2013;108(Supplement 1s):S515-S516.

Mallow PJ, Rizzo JA, Queener MK, Gathany TA, Lofland J. **Comparative efficacy of adalimumab, golimumab and infliximab in the treatment of patients with ulcerative colitis: an induction analysis.** *Am J Gastroenterol.* 2013;108(Supplement 1s):S514.

Lofland JH, Mallow P, Rizzo J. **Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.** *J Med Econ.* 2013;16(4):461-467.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The employee absenteeism costs of inflammatory bowel disease: evidence from US national survey data.** *J Occup Environ Med.* 2013;55(4):393-401.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. **Direct healthcare insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.** *Dig Dis Sci.* 2012;57(12):3080-3091.

Feagan B, Gunnarsson C, Mallow P, Rizzo J, Lofland J. **Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis.** *Can J Gastroenterol.* 2012;26:SupplSA.

Lofland J, Gunnarsson C, Mallow P, Rizzo J, Feagan B. **Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis.** *Am J Gastroenterol.* 2011;106:Suppl2:S418.

Inadomi J, Gunnarsson C, Rizzo JA, Fang H. **Projected increased growth rate of anesthesia professional-delivered sedation for colonoscopy and EGD in the United States: 2009:2015.** *Gastrointest Endosc.* 2010;72(3):580-586.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct costs of inflammatory bowel disease: evidence from United States national survey data.** *Value Health.* 2010;13(3):A206.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The indirect costs of inflammatory bowel disease: evidence from United States national survey data.** *Value Health.* 2010;13(3):A207.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct costs of inflammatory bowel disease: evidence from United States national survey data.** *Gastroenterology.* 2010;138(5)Suppl 1:S-217.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The indirect costs of inflammatory bowel disease: evidence from United States national survey data.** *Gastroenterology*. 2010;138(5)Suppl 1:S-217.

Inadomi J, Gunnarsson C, Rizzo JA, Fang H. **The predicted cost of anesthesia professionally-delivered sedation for colonoscopy and EGD in the United States and the impact of computer-assisted personalized sedation.** Poster presented at the *7th Annual World Health Care Congress* April 12-14, 2010, National Harbor, MD, USA.

## Hepatitis

Irish W, Saynisch P, Mallow PJ, Fallon L, Gunnarsson C. **Using the Medicare claims database to understand the Economic burden of Liver disease: a case study in Hepatic Encephalopathy.** *Value Health*. 2015;18(3):A226.

Tandon N, David G, Ryan M, Gunnarsson C. **Pharmacy cost of managing anemia among patients receiving chronic hepatitis C therapy.** *Med Decis Making* 2014;34(2): E95.

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and utilization of protease inhibitors in Hepatitis C (HCV) patients in a large payer database.** *J Hepatol* 2013;58 Supplement 1:S205-S206

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and drug utilization among Hepatitis C (HCV) patients in a large payer database.** *Gastroenterology*. 2013;144(5)Supplement 1:S-988-S-989.

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and drug utilization among Hepatitis C (HCV) patients in a large payer database.** *Value Health*. 2013;16(3):A211.

## Hospitals and Institutions

Rajagopalan K, Robinson SB, Ernst FR, Hunter T, Johnson BH, Bollu VK. **Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short- Acting Beta<sub>2</sub>-Agonists.** *J Clin Pathways*. 2017;4(2):37-43.

David G, Mallow PJ, Wang QC, Vartanian Fritz S, Chawla R, Nigam S. **Does Real Time Insurance Claims-Based Analysis Impacts Population Health?** Abstract presented as part of an oral presentation entitled "Using Big Data to Improve Population Health" at the conference of the *America Society of Health Economists (ASHEcon)*, June 12-15, 2016, University of Pennsylvania, Philadelphia, PA, USA.

David G, Saynisch PA, Smith-McLallen A. **The Inner Workings of the Patient-Center Medical Home Model.** Abstract presented as part of an oral presentation entitled “The Economics of Patient-Centered Medical Homes” at the conference of the *America Society of Health Economists (ASHEcon)*, June 12-15, 2016, University of Pennsylvania, Philadelphia, PA, USA.

David G, Lim S, Gunnarsson C, Kocharian R, Roy S. **Similar patient outcomes yet different hospital costs between flowable hemostatic agents.** *J Med Econ.* 2015;18(9):735-745.

Patel PA, Mallow PJ, Vassar M, Rizzo JA, Pandya BJ, Kruzikas DT. **Traumatic Brain Injury: Patient Characteristics, Hospital Costs and Trends over Time.** *JHEOR.* 2014;2(2):108-118.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **The Inner Workings of the Patient-Center Medical Home Model.** Presented at the *26<sup>th</sup> Annual Health Economics Conference (AHEC)*, October 23-24, 2015, University of Georgia, Athens, GA, USA.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do patient-centered medical homes reduce emergency department visits?** *Health Serv Res.* 2015;50(2):418-439.

David G, Lim S, Gunnarsson C, Delatore P, Kocharian R. **The effect of the choice of gelatin hemostatic matrix on hospital cost and clinical outcomes in spinal procedures.** Poster presented at the *30<sup>th</sup> Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves* March 5-8, 2014, Orlando, FL USA.

Smith-McLallen A, Helmchen L, Cruz S, Chawla, R, Gunnarsson C, Nigam S. **Impact of Rewarding Relative Performance on Health Care Quality in a Primary Care Setting.** *Med Decis Making* 2014;34(2):E91.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do Patient-Centered Medical Homes Reduce Emergency Department Visits?** Presented at the *11<sup>th</sup> Annual Southeastern Health Economics Study Group Conference* October 25-26, 2013, Baltimore, MD, USA.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do Patient-Centered Medical Homes Reduce Emergency Department Visits?** Presented at the Department of Epidemiology Seminar. *Columbia University Mailman School of Public Health* December 6, 2013, New York, NY, USA.

Mallow PJ, Pandya B, Horblyuk R, Kaplan HS. **Prevalence and cost of hospital medical errors in the general and elderly United States populations.** *J Med Econ.* 2013;16(12):1367-1378.

Mitchell A, Rohde R, Mallow P, Buskirk D. **Economic burden of methicillin-resistant *Staphylococcus aureus*, *Clostridium difficile* and vancomycin-resistant *Enterococci* in hospitals.** *Antimicrob Resist Infect Control* 2013;2(Suppl 1):P67.

Tasic D, Baker ER, Mallow P, Turgeon K. **A systematic review on the application of electrocardiographs transmitted prior to hospital arrival on door to treatment times.** *Value Health.* 2013;16(3):A294.

Rizzo JA, Gunnarsson C, Burton ML, Mollenkopf SA, Brill SL, Tsintzos S. **The cost to US hospitals for Heart Failure (HF) inpatient admissions across DRGs: a retrospective multi-center study.** *Value Health.* 2013;16(3):A282.

David G, Gunnarsson CL, Waters H, Horblyuk R, Kaplan HS. **Economic Measurement of Medical Errors Using a Hospital Claims Database.** *Value Health.* 2013;16(2):305-310.

Chawla R, Colombo C, David G, Gunnarsson C, Snyder R, Nigam S. **Patient-centered medical homes reduce inpatient admissions and expenditures for chronic members.** Poster presented at the *24th Annual National Forum on Quality Improvement in Health Care* December 9-12, 2012, Orlando, FL, USA.

Horblyuk R, Kaplan HS, Lee DW, David G, Gunnarsson C. **Applying actuarial methodology to hospital data for estimation of medical errors.** *Value Health.* 2012;15(4):A29.

Kaplan HS, Horblyuk R, Lee DW, David G, Gunnarsson C. **Measurement of medical errors using a hospital claims database.** Poster presented at the *23rd Annual National Forum on Quality Improvement in Health Care* December 4-7, 2011, Orlando, FL, USA.

Patel PA, Gunnarsson C. **A passive monitoring system in assisted living facilities: 12-month comparative study.** *Phys Occup Ther Geriatr.* 2012;30(1):45–52.

Patel PA, Gunnarsson CL. **Use of a passive monitoring system in assisted living facilities – a 12 month comparative study.** Poster presented at the *ASA 2011 Aging in America Conference* April 26–30, 2011, San Francisco, CA, USA.

## Medical Devices and Minimally Invasive Procedures

Bhattacharyya S, Gross B, Hunter TD. **A Claims-Based Analysis: Patient-Related Costs for Chronic Sinusitis & Surgery** Podium presentation at *Blue Cross Blue Shield 2018 National Summit* May 4<sup>th</sup>, 2018 Orlando Florida

Hunter TD, DeConde AS, Manes RP. **Disease-related expenditures and revision rates in chronic rhinosinusitis patients after endoscopic sinus surgery.** *Journal of Medical Economics* 2018 Apr 3:1-6.

Ernst FR, Imhoff RJ, Minshall M, DeConde AS, Manes RP. **Steroid-Eluting Sinus Implant versus Revision Surgery for Patients with Recurrent Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): an Economic Evaluation Model**



Poster accepted for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting May 19-23, 2018 in Baltimore, MD, USA

Hunter TD, DeConde AS, Manes RP. **Disease-Related Cost Burden in Patients Undergoing Sinus Surgery for Chronic Rhinosinusitis: A Claims-Based Analysis.** *Value Health.* 2016;20(9):A644.

Falowski S, Safriel Y, Ryan MP, Hargens L. **The Rate of Magnetic Resonance Imaging in Patients with Deep Brain Stimulation.** *Stereotact Funct Neurosurg.* 2016;94(3):147-153.

Sohail MR, Eby EL, Ryan MP, Wright LA, Greenspon AJ. **The Rate of CIED Infection by Severity: Evidence from a Large US Payer Database.** *Open Forum Infect Dis.* 2015;2(suppl 1):S144-S145.

Gunnarsson C, Barnett G, Walleser Autiero S, Hinnenthal J, Safriel Y, Ryan M, Conroy MJ. **Estimating the need for MRI conditionally safe deep brain stimulation systems in Parkinson's disease patients: a European perspective.** *Insights Imaging.* 2015;6(1 Supplement):S179.

Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. **The rate of magnetic resonance imaging in patients with spinal cord stimulation.** *Spine (Phila Pa 1976).* 2015;40(9):E531-E537.

Hatheway JA, Caraway D, David G, Gunnarsson C, Hinnenthal J, Ernst AR, Saulino M. **Systemic opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures.** *Neuromodulation.* 2015;18(3):207-213.

Boehme J, McKinley S, Michael Brunt L, Hunter TD, Jones DB, Scott DJ, Schwaitzberg SD. **Patient comorbidities increase postoperative resource utilization after laparoscopic and open cholecystectomy.** *Surg Endosc.* 2016;30(6):2217-2230.

Boehme J, McKinley S, Michael Brunt L, Hunter TD, Jones DB, Scott DJ, Schwaitzberg SD. **Patient comorbidities increase postoperative resource utilization after laparoscopic and open cholecystectomy.** *Surg Endosc.* 2015;29(1 Supplement):314-354.

Falowski S, Safriel Y, Ryan M, Hargens L. **The Need For Magnetic Resonance (MR) Imaging In The United States (US) Deep Brain Stimulation (DBS) Population.** *Neuromodulation.* 2015;18(2):e13-e106.

Hatheway J, Caraway D, David G, Gunnarsson C, Hinnenthal J, Ernst A, Saulino M. **Systemic Opioid Elimination after Implantation of an Intrathecal Drug Delivery System Significantly Reduced Healthcare Expenditures.** *Neuromodulation.* 2015;18(2):e13-e106.

Boehme J, McKinley SK, Brunt LM, Hunter TD, Jones DB, Scott DJ, Schwaitzberg SD. **Patient Comorbidities Increase Postoperative Resource Utilization After Laparoscopic and Open Cholecystectomy.** Poster presented at the *Massachusetts Medical Society (MMS) Ninth Annual Research Poster Symposium for Residents, Fellows, and Medical Students* December 5, 2014, Waltham, MA, USA.

Rodriguez E, Malaisrie SC, Mehall JR, Moore M, Salemi A, Ailawadi A, Gunnarsson C, Ward AF, Grossi EA; Economic Workgroup on Valvular Surgery. **Right anterior thoracotomy aortic valve replacement is associated with less cost than sternotomy-based approaches: a multi-institution analysis of "real world" data.** *J Med Econ.* 2014;17(12):846-52.

Schwaitzberg SD, Scott DJ, Jones DB, McKinley SK, Castrillion J, Hunter TD, Michael Brunt L. **Threefold increased bile duct injury rate is associated with less surgeon experience in an insurance claims database: More rigorous training in biliary surgery may be needed.** *Surg Endosc.* 2014;28(11):3068-3073.

Caraway D, Hatheway J, David G, Gunnarsson C, Hinnenthal J, Spencer R, Saulino M. **Discontinuation of Systemic Opioid Usage After Implantation of Intrathecal Drug Delivery System reduces Expenditures.** *Pain Physician.* 2014;17(3):E431.

Swanson S, Miller D, McKenna R, Meyers B, Marshall MB, Ghosh SK, Fegelman E, Roy S, Ryan M, Gunnarsson C, Howington JA. **Economic Burden of Prolonged Air Leak after Lung Resection: Open Versus Video-Assisted Thoracoscopic Surgery (VATS).** *Value Health.* 2014;17(3):A80.

Schwaitzberg SD, Scott DJ, Jones DB, McKinley SK, Castrillion J, Hunter T, Brunt LM. **Bile Duct Injury Prevention Requires a New National Training Paradigm Despite Successful Deployment of FLS.** *Surg Endosc.* 2014;28(1) Supplement:311-445.

Desai MJ, Ryan M, Hargens LM, Doth AH. **Estimating the need for Magnetic Resonance Imaging (MRI) in patients with Spinal Cord Stimulation (SCS).** *Pain Medicine.* 2014;15(3):485-537.

Grossi EA, Goldman S, Wolfe JA, Mehall JR, Smith JM, Ailawadi G, Salemi A, Moore M, Ward AF, Gunnarsson CL. **Mini-thoracotomy for Mitral Valve Repair Improves Inpatient and Post Discharge Economic Savings.** Poster presented at *American Association for Thoracic Surgery's (AATS) 94th Annual Meeting* April 26-30, 2014, Toronto, ON, Canada.

Grossi EA, Goldman S, Wolfe JA, Mehall J, Smith JM, Ailawadi G, Salemi A, Moore M, Ward A, Gunnarsson C; Economic Workgroup on Valvular Surgery. **Minithoracotomy for mitral valve repair improves inpatient and postdischarge economic savings.** *J Thorac Cardiovasc Surg.* 2014;148(6):2818-2822.e1-3.

Mallow PJ, DeRamus S, Baker ER, McKenna M. **Impact of Computer-Assisted Personalized Sedation on Components of Colonoscopy Procedure Time.** Poster presented at *25th Annual National Forum on Quality Improvement in Health Care*, December 8-11, 2013, Orlando, FL, USA.

Davis BR, Yoo AC, Moore M, Gunnarsson C. **Robotic-assisted versus laparoscopic colectomy: cost and clinical outcomes.** *JSLs*. 2014;18(2):211-224.

Desai MJ, Ryan M, Hargens L, Doth A. **Estimating the need for Magnetic Resonance Imaging (MRI) in patients with Spinal Cord Stimulation (SCS).** *Neuromodulation*. 2015;18(2):e13-e106.

Swanson SJ, Miller DL, McKenna RJ Jr, Howington J, Marshall MB, Yoo AC, Moore M, Gunnarsson CL, Meyers, BF. **Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: Results from a multihospital database (Premier).** *J Thorac Cardiovasc Surg*. 2014;147(3):929-937.

Chekan E, Moore M, Hunter TD, Gunnarsson C. **Costs and clinical outcomes of conventional single port and mini-laparoscopic cholecystectomy.** *JSLs*. 2013;17(1):30-45.

David G, Gunnarsson CL, Moore M, Howington J, Miller DL, Maddaus MA, McKenna RJ Jr, Meyers BF, Swanson SJ. **Surgeons' volume-outcome relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques.** *Minim Invasive Surg*. 2012;2012:760292.

Davis BR, Yoo AC, Moore M, Haas S, Gunnarsson C. **Comparing robot-assisted to conventional laparoscopic colectomy: impact on cost and clinical outcomes.** *Value Health*. 2012;15(4):A75.

Moore M, Yoo AC, Devadason G, Haas S, Gunnarsson C. **Comparing robot-assisted to conventional video-assisted thoracic surgical (VATS) lobectomy and wedge resection: results from a multi-hospital (Premier) database.** *Value Health*. 2012;15(4):A75.

Chekan E, Moore M, Hunter T, Gunnarsson C. **Laparoscopic cholecystectomy: a retrospective analysis of hospital costs and patient outcomes when comparing traditional laparoscopic to single port and micro-laparoscopic surgical approaches.** *Surg Endosc*. 2012;26(1) Supplement:249-430.

Howington JA, Gunnarsson CL, Maddaus MA, McKenna RJ, Meyers BF, Miller D, Moore M, Rizzo JA, Swanson S. **In-hospital clinical and economic consequences of pulmonary wedge resections for cancer using video-assisted thoracoscopic techniques vs traditional open resections: a retrospective database analysis.** *Chest*. 2012;141(2):429-435.

Patel PA, Ernst FR, Gunnarsson CL. **Evaluation of hospital complications and costs associated with using ultrasound guidance during abdominal paracentesis procedures.** *J Med Econ.* 2012;15(1):1-7.

Patel PA, Ernst FR, Gunnarsson CL. **Ultrasonography guidance reduces complications and costs associated with thoracentesis procedures.** *J Clin Ultrasound.* 2012;40(3):135-141.

Mallow P, Gunnarsson C, Rizzo JA. **Cost savings through the prevention of blood spray exposure during an umbilical cord transection.** Poster presented at the *AOHP 2011 National Conference*, September 28-October 1, 2011, Minneapolis, MN, USA.

Swanson SJ, Meyers BF, Gunnarsson CL, Moore M, Howington JA, Maddaus MA, McKenna RJ, Miller DL. **Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis.** *Ann Thorac Surg.* 2012;93(4):1027-1032.

David G, Gunnarsson CL, Moore M, Howington J, Miller D, Maddaus M, McKenna R, Meyers B, Swanson S. **Surgeon's volume-outcomes relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques.** *Value Health.* 2011;14(3):A86-A87.

Swanson SJ, Howington JA, Meyers BF, Miller DL, Maddaus MA, McKenna RJ. **Video-assisted thoracoscopic (VATS) lobectomy is less costly and morbid than open lobectomy: a retrospective multi-institution database analysis.** Poster presented at the *STS 47th Annual Meeting* January 31-February 2, 2011, San Diego, CA, USA.

Pasic RP, Rizzo JA, Fang H, Ross S, Moore M, Gunnarsson C. **Comparing robot-assisted with conventional laparoscopic hysterectomy: impact on cost and clinical outcomes.** *J Minim Invasive Gynecol.* 2010;17(6):730-738.

Howington, JA, Gunnarsson C, Maddaus MA, McKenna RJ, Miller D, Myers BF, Moore M, Swanson S. **Clinical and economic consequences of pulmonary wedge resections for cancer using video-assisted thoracoscopic techniques vs. traditional open resections: a retrospective database analysis.** *Chest.* 2010;138(4)Supp 660A.

Patel PA, Ernst FR, Gunnarsson CL. **Evaluation of hospital complications and costs associated with thoracentesis with or without ultrasound guidance.** *Chest.* 2010;138(4)Supp 333A.

Gunnarsson CL, Patel PA, Ernst FR. **Evaluation of hospital complications and costs associated with ultrasound guided paracentesis.** *Am J Gastroenterol* 2010;105 Suppl 1:S393.

Nasciben V, Rupprecht F, Moore M, Gunnarsson C. **The economic impact of contour versus hand sewn suture and other mechanical staples in low anterior resections in colon rectal cancer surgery: Interim results using real world data from Premier's hospital database.** *Value Health.* 2010;13(3):A49.

Fullum TM, Ladapo JA, Borah BJ, Gunnarsson CL. **Comparison of the clinical and economic outcomes between open and minimally invasive appendectomy and colectomy: evidence from a large commercial payer database.** *Surg Endosc.* 2010;24(4):845–853.

Warren L, Ladapo JA, Borah BJ, Gunnarsson CL. **Open abdominal versus laparoscopic and vaginal hysterectomy: analysis of a large United States payer measuring quality and cost of care.** *J Minim Invasive Gynecol.* 2009;16(5):581-588.

Gunnarsson C, Rizzo JA, Hochheiser L. **The effects of laparoscopic surgery and nosocomial infections on the cost of care: evidence from three common surgical procedures.** *Value Health.* 2009;12(1):47-54.

Moore M, Hochheiser L, Gunnarsson C, Ladapo J, Borah B. **Regional disparities and economic outcomes associated with minimally invasive and conventional surgeries of the chest, abdomen, and pelvis.** *Value Health.* 2009;12(3):A63

Warren L, Ladapo JA, Borah B, Gunnarsson C. **Abdominal vs. laparoscopic and vaginal hysterectomy: analysis of a large US payer measuring quality & cost of care.** Podium presentation at *Global Congress of Minimally Invasive Gynecology (AAGL) 38<sup>th</sup> Annual Meeting* November 15-19, 2009, Orlando, FL, USA.

Brill A, Ghosh K, Gunnarsson C, Rizzo J, Fullum T, Maxey C, Brossette S. **The effects of laparoscopic cholecystectomy, hysterectomy, and appendectomy on nosocomial infection risks.** *Surg Endosc.* 2008;22(4):1112-1118.

Rizzo J, Gunnarsson C, Hochheiser L, Moore M. **The effects of laparoscopic surgery and nosocomial infections on the cost of care: evidence from three surgical procedures.** *Value Health.* 2007;10(6):A474

## Orthopedics

Chen J, Rizzo JA, Parasuraman S, Gunnarsson C. **Racial disparities in receiving total hip/knee replacement surgery: the effect of hospital admission sources.** *J Health Care Poor Underserved.* 2013;24(1):135-151.

Kotlarz H, Chen J, Rizzo J, Gunnarsson C. **Racial and ethnic disparities in total knee replacement surgery.** *Value Health.* 2010;13(3):A132.

Kotlarz H, Chen J, Rizzo J, Gunnarsson C. **Racial and ethnic disparities in total hip replacement surgery.** *Value Health.* 2010;13(3):A132.

Peoples S, Rizzo J, Kotlarz H. **Health economics model for total hip arthroplasty: cost savings achieved by newer technology.** *Value Health.* 2008;11(3):A256-A257.

## Osteoarthritis

Kotlarz H, Gunnarsson C, Fang H, Rizzo J. **Osteoarthritis and absenteeism costs: evidence from U.S. National survey data.** *J Occup Environ Med.*2010;52(3):263-268. Article accepted for Continuing Medical Education (CME).

Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. **Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data.** *Arthritis Rheum.* 2009;60(12):3546-3553.

Kotlarz H, Gunnarsson C, Rizzo J. **Osteoarthritis and job absenteeism costs: Evidence from U.S. national survey data.** *Value Health.* 2008;11(6):A546.

Kotlarz H, Gunnarsson C, Rizzo J. **The direct health care costs of osteoarthritis: evidence from U.S. national survey data.** *Value Health.* 2008;11(6):A546.

## Rare Diseases

Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, Prasad S, Winslow BJ. **Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults with Phenylketonuria.** *Dev Neuropsychol.* 2016;41(4):245-260

Bilder DA, Noel JK, Baker E, Irish W, Winslow BJ, Jain R, Chen Y, Merilainen MJ, Prasad S. **A systematic review (SR) and meta-analysis (MA) to assess the prevalence of neuropsychiatric symptoms in adults with phenylketonuria (PKU).** *J Inherit Metab Dis.* 2014;37(Suppl 1):S178.

Bilder DA, Noel JK, Baker ER, Irish W, Winslow BJ, Jain R, Chen Y, Merilainen MJ, Prasad S. **A systematic review (SR) and meta-analysis (MA) to assess blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU).** *J Inherit Metab Dis.* 2014;37(Suppl 1):S178.

Bilder DA, Noel JK, Baker ER, Irish W, Winslow BJ, Jain R, Chen Y, Prasad S, Merilainen MJ. **A systematic review (SR) of the effectiveness of reducing blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU) on neuropsychiatric symptoms.** *J Inherit Metab Dis.* 2014;37(Suppl 1):S62.



## Research Methods

Johnson AN. **Human Gene Editing and Advanced Therapies: How will FDA, EMA, and Gene Therapy Mix?** *Regulatory Affairs Professionals (RAPS) Convergence*. October 1-4, 2018. Vancouver, BC.

Johnson AN. **If You Can Write a Grant, You Can Write a Pitch Deck.** Annual Conference of the American Medical Writers Association (AMWA) Washington DC, November 1-3 2018

Johnson AN. **Leaping from Desk to Podium: Essential Presentation Skills for Medical Writers.** Annual Conference of the American Medical Writers Association (AMWA) Washington DC, November 1-3 2018

Johnson AN. **Gene Therapy Harmonization Milestones and Challenges.** *Regulatory Focus*. May 2018. [in press]

Johnson AN. **The Gap between Clinician-Led Cell Therapy Evidence and Marketed Products: a Quasi-Experimental Comparative Pilot Study of Young Venture Clinical Development.** *Molecular Therapy*. 2018;26(5S1):429.

Johnson AN. **Virtual and Augmented Reality as Game-Changers in Anesthesiology: History, Applications, and Challenges for Clinical Virtuality.** *J Anest & Inten Care Med*. 2018;5(1):555652.

Hunter TD, Muirheid, L. **The Impact of the Centers for Medicare and Medicaid Services (CMS) 2016 Update to the Two-Midnight Rule on Inpatient/Outpatient Status and Length of Stay for Cardiac Ablation Procedures.** Poster accepted for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting May 19-23, 2018 in Baltimore, MD, USA

Johnston SS, Gagne J, Ernst FR, Chitnis AS. **Medical Device Real-World Evidence for Beginners: A Primer.** Workshop presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting May 19-23, 2018 in Baltimore, MD, USA

David G, Johnson M, Lim L, Mallow PJ. **Selection of Statistical Approach in Understanding the Role of Contrast Media in Inpatient Interventional Cardiovascular Procedures.** *Value Health*. 2015;18(7):A682-A683.

Nakagawa JA, Irish W, Ryan M, Womeldorff J, Roberds SL. **Symptoms of tuberous sclerosis complex: comparison of TSC1 versus TSC2 gene mutation.** Poster presented at *2015 International Research Conference on Tuberous Sclerosis Complex: from Treatment to Prevention*. September 10-12, 2015, Windsor, UK.

Sietsema W, Wekselman K. **Agency Meetings with the US Food and Drug Administration.** *Regulatory Focus*. April 2015. Regulatory Affairs Professionals Society.

Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. **Adjusting for comorbidities in cost of illness studies.** *J Med Econ*. 2015;18(1):12-28.

Cload P, Mallow P, Mako J, Gunnarsson C. **Data visualization for business intelligence: assessing an online tool used for benchmarking hospital procedure costs to reimbursement in cardiac catheterization and electrophysiology procedures.** *Value Health*. 2011;14(7):A254.

Crawford A, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, Haas S, Nigam S, Schuette R, Yaskin J. **Comparison of GE Centricity electronic medical record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States.** *Popul Health Manag*. 2010;13(3):139-150.

Rizzo J, Gunnarsson C, Zyczynski T, Ryan A. **Methods for imputing health care expenditure data across operational databases: evidence based decision making through innovations with database visualization.** Podium presentation at *ISPOR - 15th Annual International Meeting* May 15-19, 2010, Atlanta, GA, USA.

Crawford A, Gunnarsson C, Haas K, Nigam S, Couto J. **The utilization of outpatient electronic health record systems data for outcomes and quality research: Strengths, weaknesses and lessons learned: a case study using the GE Centricity EHR.** Podium presentation at *ISPOR - 14th Annual International Meeting* May 16-20, 2009, Orlando, FL, USA.

Gunnarsson C, Ross S. **Health technology assessments in Asian-Pacific countries.** Podium presentation at *ISPOR - 3rd Asia-Pacific Conference* September 7-9, 2008, Seoul, South Korea.

**Therapeutic nutritional products: Use of evidence-based medicine to support health claims.** *Worldnutra 2005 - 6th International Conference & Exhibition on Nutraceuticals and Functional Foods* October 16-19, 2005, Anaheim, CA, USA.

## Rheumatology

Teeple A, Ryan M, Muirheid L, Ellis L. **Healthcare Resource Utilization and Infection Risk in Rheumatoid Arthritis Patients with and without Comorbidities.** *Ann Rheum Dis*. 2016;75(Suppl2):644.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence from US National Survey Data.** *J Occup Environ Med*. 2015;57(6):635-642.

David G, Tandon N, Waters HC, Gunnarsson C, Kavanaugh A. **Rheumatoid Arthritis and Joint Replacement: Impact of Biologics.** *Am J Pharm Benefits.* 2014;6(6):256-264.

Carter C, Haas S, Gunnarsson C, Martin S. **Comparison of methods for the evaluation of ustekinumab dosing and costs in pharmacy claims databases.** *Value Health.* 2012;15(4):A162-A163.

Carter C, Haas S, Gunnarsson C, Martin S. **Longitudinal analysis of ustekinumab dosing in patients with or without prior biologic experience in the Wolters Kluwer Source® Lx National Health Claims Database.** *Value Health.* 2012;15(4):A16.

Ellis L, Haas S, Tandon N. **Dosing and refill compliance in ankylosing spondylitis patients treated with golimumab.** *Value Health.* 2012;15(4):A105.

Ellis L, Haas S, Tandon N. **Observed dosing and refill compliance in psoriatic arthritis patients treated with golimumab.** *Value Health.* 2012;15(4):A41.

Ellis L, Haas S, Tandon N. **Golimumab dosing and refill compliance patterns in rheumatoid arthritis.** *Value Health.* 2012;15(4):A40.

Schmeichel-Mueller S, Gunnarsson C, Martin S. **Determining accurate dosing of ustekinumab from Specialty Pharmacy data.** *Value Health.* 2012;15(4):A254.

Tandon N, Haas S, Bolge S, Gunnarsson C. **Patient characteristics and golimumab utilization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients.** *Value Health.* 2012;15(4):A48.

Tandon N, Haas S, Waters H, Olson W, Bolge S, Gunnarsson C. **Persistency with subcutaneous anti-TNF therapy for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients.** *Value Health.* 2012;15(4):A41.

Tandon N, David G, Kavanaugh A, Gunnarsson C. **The impact of biologics for the treatment of rheumatoid arthritis.** *J Manag Care Pharm.* 2012;18(2):181-182.

Tandon N, David G, Kavanaugh A, Gunnarsson C. **The impact of biologics for the treatment of rheumatoid arthritis: the case of total hip and knee replacement surgery.** *Arthritis Rheum.* 2011;63(10 Suppl):912.

Ellis L, Ryan A, Haas S, Gunnarsson C, Tandon, N. **Longitudinal analysis of golimumab utilization: evidence from the Wolters Kluwer Source LX National Health Claims Database.** *J Manag Care Pharm.* 2011;17(7):562-563.

Ellis L, Tandon N, Mody S, Doshi D, Beak C, Gunnarsson CL. **Characteristics of golimumab utilization and costs in a specialty pharmacy provider (SPP) setting.** *Value Health.* 2011;14(3):A70.

Tandon N, Saulnier A, Gunnarsson CL. **Characteristics of golimumab utilization in a large national payer database.** *Value Health.* 2011;14(3):A71.

Tandon N, Carter C, Haas S, Gunnarsson CL. **GE Centricity electronic medical records study: comorbidities and biologic experience among patients receiving golimumab.** *Value Health.* 2011;14(3):A70-A71.

Carter C, Haas S, Gunnarsson CL, Rizzo JA, Ingham M. **Longitudinal analysis of infliximab dosing and infusion intervals across 30 infusions.** *Value Health.* 2011;14(3):A70.

Carter C, Gunnarsson CL, Rizzo JA, Bolge S, Ingham M. **Economic consequences of under-utilization with tumor necrosis factor inhibitors in rheumatoid arthritis patients.** *Value Health.* 2011;14(3):A70.

Carter CT, Rizzo JA, Gunnarsson CL, Bolge SC. **Consistency of maintenance infliximab weight-based dosing and administration patterns in commercially insured patients with rheumatoid arthritis.** *J Manag Care Pharm.* 2011;17(3):240.

Carter C, Rizzo J, Gunnarsson CL, Bolge SC, Mody SH. **Rates and economic consequences of rheumatoid arthritis patients receiving less-than-recommended labeled dosing of adalimumab and etanercept.** *J Manag Care Pharm.* 2010;16(7):544-545.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S, Mody S. **Differences in demographics and pre-index health care utilization and costs in patients with rheumatoid arthritis taking anti-TNF biologics during the first year of persistent therapy.** *Value Health.* 2010;13(3):A134.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S. **Alternative approaches for estimating drug dosing in the treatment of rheumatoid arthritis: the case of infliximab.** *Value Health.* 2010;13(3):A134.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S, McKenzie RS. **An event-level analysis of prescription refill intervals for adalimumab and etanercept in the treatment of rheumatoid arthritis.** *Value Health.* 2010;13(3):A128.

Bolge S, Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J. **The direct medical costs of rheumatoid arthritis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A124.

Naim A, Lofland J, Bolge S, Rizzo J, Gunnarsson C, Chen J. **The indirect costs associated with absenteeism of working adults with rheumatoid arthritis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A124.

## Transplantation

Agarwal S, Brandman D, Živković SA, Irish W, Gache LM, McManus A, Gollob J, Lin H, Partisano AM. **Characteristics of Patients with Hereditary Transthyretin-Mediated Amyloidosis on the US Liver Transplant Waiting List** *Orphanet Journal of Rare Diseases*. 2017;12(Suppl 1):P41

Irish W. **Conducting Clinical Studies in Low Incidence/Rare Conditions: Scientific Challenges and Study Design Considerations**. Oral presentation at *Antibody Mediated Rejection in Kidney Transplantation; Public Workshop*, April 12-13, 2017, Silver Spring, MD, USA.

Tedesco H, Irish W, Dharmesh K, Patel D, Cibrik D. **Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx)**. *Am J Transplant*. 2017;17(suppl 3):740.

Ojo A, Agashivala N, Gache L, Irish W. **Twenty Year Trends in Outcomes and Costs Following Kidney Transplantation**. *Am J Transplant*. 2017;17(suppl 3):390-391.

Irish W, Ojo AO, Agashivala N, Gache LM. **20-Year Trends in Clinical Outcomes of Kidney Transplantation**. *J Am Soc Nephrol*. 2016;27:45A.

Cibrik D, Irish W, McCague KM, Patel D, Tedesco-Silva H. **Long-Term Outcomes with Everolimus (EVR) and Other Regimens in Kidney Transplantation in the United States**. *J Am Soc Nephrol*. 2016;27:621A.

Lee E, Perry AR, Facklam D, Schwartz JJ, Franks B, Thal G, Spalding JR, Vassilakis ME, Irish W. **Impact of Tacrolimus Formulation Switching on Trough Variability**. *J Am Soc Nephrol*. 2016;27:619A.